– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA ...
Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.
A new urine test performed better than PSA-based testing and MRI for monitoring low-risk prostate cancers on active ...
Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...
The first OnQ Prostate-assisted Focal One® Robotic HIFU procedure was successfully performed at UCSF, improving prostate cancer treatment precision. Cortechs.ai and EDAP TMS have announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results